NCT06335667 mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer
| NCT ID | NCT06335667 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Irvine |
| Condition | Urothelial Bladder Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-03-27 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-03-27 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pilot, single arm, prospective study that aims to validate the accuracy of the VI-RADS score obtained via multi-parametric magnetic resonance imaging (mpMRI) compared to pathologic cancer stage obtained via diagnostic transurethral bladder tumor resection (TURBT) as well as compare the clinical and quality of life outcomes between these diagnostic modalities in patients with suspected muscle-invasive bladder cancer (MIBC).
Eligibility Criteria
Inclusion Criteria: * Age 18 years old or greater at the time of consent. * Suspected muscle-invasive bladder cancer by tumor appearance on initial routine cystoscopy as determined by the UCI-affiliated provider performing this procedure. * ECOG Performance Status of 0-3. * Patients must have the ability to understand and the willingness to sign a written informed consent document (prior to the initiation of the study and any study procedures). * Patients must be willing and able to comply with the scheduled visits, imaging plan, follow up plan, and other specified study procedures in the opinion of the Investigator. Exclusion Criteria: * Prior TURBT within 120 days of study entry. * Prior therapy for bladder cancer within 180 days of study entry. * Inability to tolerate mpMRI or associated contrast. * Inability to tolerate TURBT or associated anesthesia. * ECOG Performance Status of 4. * Female patient who is known to be pregnant or breastfeeding.
Contact & Investigator
Chao Family Comprehensive Cancer Center University of California, Irvine
✉ ucstudy@uci.edu📞 1-877-827-8839
Nataliya Mar, MD
PRINCIPAL INVESTIGATOR
Chao Family Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06335667 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Urothelial Bladder Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06335667 currently recruiting?
Yes, NCT06335667 is actively recruiting participants. Contact the research team at ucstudy@uci.edu for enrollment information.
Where is the NCT06335667 trial being conducted?
This trial is being conducted at Orange, United States.
Who is sponsoring the NCT06335667 clinical trial?
NCT06335667 is sponsored by University of California, Irvine. The principal investigator is Nataliya Mar, MD at Chao Family Comprehensive Cancer Center. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.